KPTI - NASDAQ
Karyopharm Therapeutics Inc.
$9.23
+2.3%Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
At a Glance
Live SnapshotKaryopharm Therapeutics Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Karyopharm Therapeutics Inc. Income Statement
KPTI • NASDAQ
| Karyopharm Therapeutics Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||||
146.1M | 145.2M | 146M | 157.1M | 209.8M | 108.1M | 40.9M | 30.3M | 1.6M | 154K | 250K | 229K | 387K | 634K | 152K | |
GROSS PROFIT | |||||||||||||||
(5.9M) | (6M) | (4.9M) | (5.2M) | (3.4M) | (2.7M) | (2.4M) | (161.4M) | (107.3M) | (86.9M) | (97.7M) | (60.1M) | (28.5M) | (14.1M) | (0.0) | |
140.1M | 139.2M | 141.1M | 151.9M | 206.4M | 105.4M | 38.5M | -131M | -105.7M | -86.8M | -97.5M | -59.9M | -28.1M | -13.5M | 152K | |
OPERATING INCOME | |||||||||||||||
(230.8M) | (258.7M) | (270.6M) | (294.1M) | (304.7M) | (277.2M) | (227.8M) | (210.2M) | (132.1M) | (110.9M) | (119.3M) | (76.1M) | (34.3M) | (16.5M) | (10.5M) | |
(105.2M) | (115.4M) | (131.9M) | (145.4M) | (143.8M) | (126.4M) | (105.4M) | (48.8M) | (24.9M) | (23.9M) | (21.6M) | (15.9M) | (5.9M) | (2.4M) | (1.8M) | |
(125.6M) | (143.2M) | (138.8M) | (148.7M) | (160.8M) | (150.8M) | (122.3M) | (161.4M) | (107.3M) | (86.9M) | (97.7M) | (60.1M) | (28.5M) | (14.1M) | (8.6M) | |
-90.7M | -119.4M | -129.5M | -142.2M | -98.3M | -171.9M | -189.3M | -179.9M | -130.5M | -110.7M | -119.1M | -75.8M | -34M | -15.9M | -10.3M | |
PRE-TAX INCOME | |||||||||||||||
(45.8M) | (37.4M) | (23.8M) | (25M) | (26M) | (27.1M) | (15.6M) | (2.5M) | (0.0) | (0.0) | (0.0) | (1K) | (0.0) | (0.0) | (0.0) | |
-43.1M | -30M | -12.9M | -22.6M | -25.5M | -24.3M | -10.2M | 1.5M | 1.7M | 1.3M | 897K | 96K | 3K | 2K | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -33K | -81K | (10K) | -2K | -27K | (0.0) | (0.0) | (0.0) | |
-105.3M | 43.1M | -13.2M | -22.7M | -25.5M | -24.1M | -10.3M | 1.5M | 1.6M | 1.3M | 895K | 69K | 3K | 2K | 0.0 | |
-196M | -76.4M | -142.8M | -164.9M | -123.8M | -196M | -199.6M | -178.4M | -128.9M | -109.4M | -118.2M | -75.8M | -33.9M | -15.9M | -10.3M | |
NET INCOME | |||||||||||||||
(43K) | (57K) | (323K) | (369K) | (268K) | (309K) | (40K) | (26K) | (63K) | (139K) | -895K | -69K | -3K | -2K | (0.0) | |
-196M | -76.4M | -143.1M | -165.3M | -124.1M | -196.3M | -199.6M | -178.4M | -129M | -109.6M | -118.2M | -75.8M | -33.9M | -15.9M | -10.3M |
SEC Filings
KPTI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 28, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
S-3 S-3 N/A | May 04, 2026 | May 04, 2026 | ||
S-3 S-3 N/A | May 04, 2026 | May 04, 2026 | ||
DEF 14A DEF 14A 2026 N/A | April 13, 2026 | April 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 03, 2026 | February 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 18, 2026 | 2026 |
Related Guides
Continue your KPTI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.